ABNOM
relevance score : -100.0%
ReferencesQ‑switched Nd:YAG レーザーは、太田母斑および同様の病変に対して効果的であることが知られています。私たちは、皮膚を漂白せずに、異常領域の蒙古斑に対する high‑fluence 1064 nm Q‑switched Nd:YAG レーザーの有効性を検討する研究を実施しました。太田母斑を有する 61 人の患者（合計 70 個の病変）を対象とし、病変の半数をレーザーで治療し、残りは比較のために未治療としました。治療効果は、スケールとメラニン濃度を測定できる Mexameter® を用いて評価しました。治療群は平均 14 か月、観察群は平均 18 か月の追跡期間がありました。研究終了時、治療群と未治療群の間でスケールスコアおよびメラニンレベルに有意差が認められ、レーザー治療群の方がより良好な結果を示しました。high‑fluence Q‑switched Nd:YAG レーザーは、皮膚の美白を引き起こすことなく、これらの異常な蒙古斑の治療に効果的かつ安全であることが示されました。
The Q-switched Nd:YAG laser is known to effectively treat nevus of Ota and similar conditions. We conducted a study to see how well a high-fluence 1064 nm Q-switched Nd:YAG laser worked on Mongolian spots in unusual areas, without causing the skin to lighten. We studied 61 patients with these spots, examining a total of 70 lesions. Half of lesions were treated with the laser, while others were left untreated for comparison. We evaluated the results using a scale and a device called a Mexameter® to measure melanin levels. Patients were followed up for an average of 14 months in the treatment group and 18 months in the observation group. At the end of the study, we found significant differences in the scale scores and melanin levels between the treated and untreated groups, with the laser-treated group showing better outcomes. The high-fluence Q-switched Nd:YAG laser, without causing skin lightening, proved effective and safe for treating these unusual Mongolian spots.
The Q-switched Nd:YAG laser is known to effectively treat nevus of Ota and similar conditions. We conducted a study to see how well a high-fluence 1064 nm Q-switched Nd:YAG laser worked on Mongolian spots in unusual areas, without causing the skin to lighten. We studied 61 patients with these spots, examining a total of 70 lesions. Half of lesions were treated with the laser, while others were left untreated for comparison. We evaluated the results using a scale and a device called a Mexameter® to measure melanin levels. Patients were followed up for an average of 14 months in the treatment group and 18 months in the observation group. At the end of the study, we found significant differences in the scale scores and melanin levels between the treated and untreated groups, with the laser-treated group showing better outcomes. The high-fluence Q-switched Nd:YAG laser, without causing skin lightening, proved effective and safe for treating these unusual Mongolian spots.
私たちは、ABNOMに対する特定のレーザー治療の有効性と安全性を研究し、効果に影響する要因を検討しました。ABNOMを患い、2～9回のレーザー治療を受けた110人の患者を対象としました。この治療は、施術回数が増えるほど効果が高まりますが、高齢者には効果が見られませんでした。また、皮膚の色が薄い（III型）患者や、病変面積が小さい（10 cm²未満）患者でも効果が認められました。ABNOMに加えて肝斑があると、治療効果が低下します。影響を受けた領域の色や数に差は見られませんでした。約10%の患者で、治療後にシミが濃くなることが報告されました。早期に複数回の治療を行うことで、良好な結果が得られます。肌の色が濃く、シミも濃い高齢患者は、治療後にシミが濃くなるリスクが高くなります。ABNOMおよび肝斑の患者では、肝斑の悪化を防ぐために低エネルギーのレーザーを使用する方が適しています。
To evaluate the efficacy and safety of 1064-nm Q-switched Nd:YAG laser (QSNYL) therapy for ABNOM and to identify the factors influencing the outcome. A total of 110 patients with ABNOM were retrospectively evaluated and received two-to-nine treatment sessions. The curative effect was positively correlated with the treatment time and negatively correlated with the increasing age at first treatment (p < 0.05). The curative effect was better in patients with skin type III than those with type IV ( p < 0.05) and in patients with a lesion area of less than 10 cm2 than those with a larger affected area (p < 0.05). Additionally, the treatment effect was poorer in patients with concomitant melasma (p < 0.05). The treatment effect was not significantly correlated with the lesion color or number of affected sites (p > 0.05). Eleven patients (10%) developed postinflammatory hyperpigmentation (PIH). Early and repeated QSNYL therapy achieved satisfactory results for ABNOM. The risk of PIH after laser treatment is highest among patients with older age, darker lesion color, and darker skin color. For patients with ABNOM with concurrent melasma, low-energy laser therapy is recommended to reduce the risk of melasma aggravation.
To evaluate the efficacy and safety of 1064-nm Q-switched Nd:YAG laser (QSNYL) therapy for ABNOM and to identify the factors influencing the outcome. A total of 110 patients with ABNOM were retrospectively evaluated and received two-to-nine treatment sessions. The curative effect was positively correlated with the treatment time and negatively correlated with the increasing age at first treatment (p < 0.05). The curative effect was better in patients with skin type III than those with type IV ( p < 0.05) and in patients with a lesion area of less than 10 cm2 than those with a larger affected area (p < 0.05). Additionally, the treatment effect was poorer in patients with concomitant melasma (p < 0.05). The treatment effect was not significantly correlated with the lesion color or number of affected sites (p > 0.05). Eleven patients (10%) developed postinflammatory hyperpigmentation (PIH). Early and repeated QSNYL therapy achieved satisfactory results for ABNOM. The risk of PIH after laser treatment is highest among patients with older age, darker lesion color, and darker skin color. For patients with ABNOM with concurrent melasma, low-energy laser therapy is recommended to reduce the risk of melasma aggravation.
○ 処理
ホワイトニング剤が有効になることはほとんどありません。肝斑とは異なり、ABNOM はレーザー治療で改善でき、再発せずに除去できます。ABNOM の治療には、レーザーを 10〜20 回施行します。
#QS1064 laser